Facebook Twitter LinkedIn Google Plus RSS

PTC Therapeutics appoints chief commercial officer

By ,

South Plainfield-based PTC Therapeutics, Inc. announced Tuesday the appointment of Mark A. Rothera as chief commercial officer, responsible for global commercial functions supporting PTC's pipeline, including the investigational new drug ataluren.

A veteran of the orphan drug arena, Mr. Rothera has spent 15 of his 23 years in the biopharmaceutical industry, according to a release. He served previously as global president of Aegerion Pharmaceuticals Inc.

Also Popular on NJBIZ

Write to the Editorial Department at editorial@njbiz.com

Leave a Comment


Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy